托里消毒散加减通过PI3K/Akt/mTOR通路调节炎症反应改善肉芽肿性乳腺炎的作用机制研究OA
Study on the mechanism of modified Tuoli Xiaodu San in ameliorating granulomatous mastitis through regulation of inflammatory responses via the PI3K/Akt/mTOR signaling pathway
目的:探讨托里消毒散加减通过磷酸肌醇3激酶(PI3K)/蛋白激酶B(Akt)/哺乳动物雷帕霉素靶蛋白(mTOR)信号通路调节炎症反应改善肉芽肿性乳腺炎(GM)的作用机制.方法:采用人体GM病变组织匀浆与弗氏完全佐剂混合液注射法建立SD大鼠GM模型.另取12只健康大鼠分为正常组(n=6,不施任何造模处理)和佐剂对照组(n=6,仅注射等量弗氏完全佐剂).将60只造模成功的大鼠随机分为五组(每组初始n=12):模型组、甲氨蝶呤阳性对照组(0.35 mg/kg,每周1次)、托里消毒散低剂量组(4.5 g/kg)、中剂量组(8.9 g/kg)和高剂量组(17.8 g/kg);实验期间共剔除2只(因操作应激死亡,依据预设剔除标准),最终每组纳入统计n=10.连续给药8周后,观察各组大鼠乳腺炎症指数评分;HE染色观察乳腺组织病理学改变;免疫组织化学法(×400倍)检测乳腺组织 Bcl-2 相关 X 蛋白(Bax)、B 细胞淋巴瘤-2(Bcl-2)蛋白表达;Western blot 法检测 PI3K、p-PI3K、Akt、p-Akt、mTOR、p-mTOR蛋白表达水平;RT-qPCR法检测PI3K、Akt、mTOR mRNA表达水平;ELISA法检测血清白介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、白介素-1β(IL-1β)水平.结果:佐剂对照组各检测指标与正常组比较均无统计学差异(P>0.05),提示弗氏完全佐剂不引起非特异性免疫干扰.与模型组比较,托里消毒散各剂量组大鼠乳腺炎症指数评分显著降低(P<0.05),其中高剂量组效果最佳(P<0.01).HE染色显示托里消毒散各剂量组炎性细胞浸润减少,肉芽肿结构明显改善.免疫组织化学结果显示,托里消毒散高剂量组Bax蛋白表达较模型组显著降低(P<0.01),Bcl-2蛋白表达显著升高(P<0.01),Bax/Bcl-2比值由2.90降至0.52.Western blot结果表明,托里消毒散高剂量组p-PI3K/PI3K、p-Akt/Akt、p-mTOR/mTOR比值较模型组显著降低(P<0.01).RT-qPCR结果显示,托里消毒散各剂量组PI3K、Akt、mTOR mRNA表达水平呈剂量依赖性降低(P<0.05).ELISA结果表明,托里消毒散高剂量组血清IL-6、TNF-α、IL-1β水平较模型组显著降低(P<0.01).结论:托里消毒散加减可能通过抑制PI3K/Akt/mTOR信号通路激活、下调促炎因子(IL-6、TNF-α、IL-1β)表达及调节Bax/Bcl-2凋亡蛋白平衡,从而发挥抗炎作用,改善乳腺组织炎症微环境,减轻GM病理损伤.
Objective:To investigate the mechanism by which modified Tuoli Xiaodu San ameliorates granuloma-tous mastitis(GM)through regulation of inflammatory responses via the PI3K/Akt/mTOR signaling pathway.Methods:A rat GM model was established in SD rats by subcutaneous injection of a mixture of homogenized human GM lesion tissue and Freund's complete adjuvant.An additional 12 healthy rats were assigned to a normal control group(n=6)and an adjuvant control group(n=6,injected with Freund's adjuvant alone).Sixty rats with successful-ly induced GM were randomized into five groups(initial n=12 each):a model group,a methotrexate positive control group(0.35 mg/kg,once weekly),and low-,medium-,and high-dose Tuoli Xiaodu San groups(4.5,8.9,and 17.8 g/kg,respectively).Two rats died from procedural stress and were excluded according to pre-specified criteria,yielding a fi-nal sample size of n=10 per group.After 8 weeks of treatment,the mammary inflammation index was scored;his-topathological changes were examined by HE staining;Bax and Bcl-2 expression was assessed by immunohistochem-istry(×400);PI3K,p-PI3K,Akt,p-Akt,mTOR,and p-mTOR protein levels were measured by Western blot;corre-sponding mRNA levels were quantified by RT-qPCR;and serum IL-6,TNF-α,and IL-1β were detected by ELISA.Results:No significant differences were observed between the adjuvant control and normal groups for any measured index(P>0.05),indicating that Freund's adjuvant alone did not elicit non-specific immune interference.Compared with the model group,all Tuoli Xiaodu San groups showed significantly reduced inflammation index scores(P<0.05),with the greatest reduction in the high-dose group(P<0.01).HE staining revealed attenuated inflammatory cell infiltration.Immunohistochemistry showed that,compared with the model group,the high-dose group had signifi-cantly lower Bax expression(P<0.01)and higher Bcl-2 expression(P<0.01),with the Bax/Bcl-2 ratio decreasing from 2.90 to 0.52.Western blot analysis revealed significant reductions in the p-PI3K/PI3K,p-Akt/Akt,and p-mTOR/mTOR ratios(P<0.01),and ELISA showed marked decreases in serum IL-6,TNF-α,and IL-1β(P<0.01).Conclusion:Modified Tuoli Xiaodu San may ameliorate GM by inhibiting activation of the PI3K/Akt/mTOR signaling pathway,down-regulating pro-inflammatory cytokines(IL-6,TNF-α,IL-1β),and modulating the Bax/Bcl-2 apoptotic balance,thereby improving the inflammatory microenvironment of mammary tissue.
袁鸿;王薇;郑天丽;刘慧芳;马震
新疆医科大学第五附属医院乳腺外科,新疆乌鲁木齐 830011新疆医科大学第五附属医院乳腺外科,新疆乌鲁木齐 830011新疆医科大学第五附属医院乳腺外科,新疆乌鲁木齐 830011新疆医科大学第五附属医院乳腺外科,新疆乌鲁木齐 830011马来西亚泰莱大学医学科学院,马来西亚雪兰莪州47500
医药卫生
肉芽肿性乳腺炎托里消毒散PI3K/Akt/mTOR信号通路炎症反应细胞凋亡白细胞介素-6
Granulomatous mastitisTuoli Xiaodu SanPI3K/Akt/mTOR signaling pathwayInflammatory responseApoptosisInterleukin-6
《陕西中医》 2026 (9)
1174-1182,9
新疆维吾尔自治区自然科学基金资助面上项目(2024D01C158)
评论